AJP - Heart Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 293: H928-H938, 2007. First published May 4, 2007; doi:10.1152/ajpheart.01135.2006
0363-6135/07 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/2/H928    most recent
01135.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Townsend, P. A.
Right arrow Articles by Halestrap, A. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Townsend, P. A.
Right arrow Articles by Halestrap, A. P.

Urocortin prevents mitochondrial permeability transition in response to reperfusion injury indirectly by reducing oxidative stress

Paul A. Townsend,1,2,* Sean M. Davidson,3,* Samantha J. Clarke,4 Igor Khaliulin,4 Christopher J. Carroll,2 Tiziano M. Scarabelli,5 Richard A. Knight,2 Anastasis Stephanou,2 David S. Latchman,2 and Andrew P. Halestrap4

1Human Genetics Division, University of Southampton, Southampton; and 2Institute of Child Health and 3The Hatter Institute and Centre for Cardiology, University College London, London; and 4Biochemistry Department, University of Bristol, Bristol, United Kingdom; and 5Center for Heart and Vessel Preclinical Studies, Wayne State University, Detroit, Michigan

Submitted 16 October 2006 ; accepted in final form 4 May 2007

Urocortin (UCN) protects hearts against ischemia and reperfusion injury whether given before ischemia or at reperfusion. Here we investigate the roles of PKC, reactive oxygen species, and the mitochondrial permeability transition pore (MPTP) in mediating these effects. In Langendorff-perfused rat hearts, acute UCN treatment improved hemodynamic recovery during reperfusion after 30 min of global ischemia; this was accompanied by less necrosis (lactate dehydrogenase release) and MPTP opening (mitochondrial entrapment of 2-[3H]deoxyglucose). UCN pretreatment protected mitochondria against calcium-induced MPTP opening, but only if the mitochondria had been isolated from hearts after reperfusion. These mitochondria also exhibited less protein carbonylation, suggesting that UCN decreases levels of oxidative stress. In isolated adult and neonatal rat cardiac myocytes, both acute (60 min) and chronic (16 h) treatment with UCN reduced cell death following simulated ischemia and re-oxygenation. This was accompanied by less MPTP opening as measured using tetramethylrhodamine methyl ester. The level of oxidative stress during reperfusion was reduced in cells that had been pretreated with UCN, suggesting that this is the mechanism by which UCN desensitizes the MPTP to reperfusion injury. Despite the fact that we could find no evidence that either PKC-{varepsilon} or PKC-{alpha} translocate to the mitochondria following acute UCN treatment, inhibition of PKC with chelerythrine eliminated the effect of UCN on oxidative stress. Our data suggest that acute UCN treatment protects the heart by inhibiting MPTP opening. However, the mechanism appears to be indirect, involving a PKC-mediated reduction in oxidative stress.

mitochondria; oxygen radicals; peptide hormones



Address for reprint requests and other corespondence: P. A. Townsend, Human Genetics Div., Duthie Bldg., MP808, Southampton General Hospital, Univ. of Southampton, Tremona Rd., Southampton, SO16 6YD, UK (e-mail: p.a.townsend{at}soton.ac.uk)




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
F. N. Obame, C. Plin-Mercier, R. Assaly, R. Zini, J. L. Dubois-Rande, A. Berdeaux, and D. Morin
Cardioprotective Effect of Morphine and a Blocker of Glycogen Synthase Kinase 3{beta}, SB216763 [3-(2,4-Dichlorophenyl)-4(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione], via Inhibition of the Mitochondrial Permeability Transition Pore
J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 252 - 258.
[Abstract] [Full Text] [PDF]


Home page
PhysiologyHome page
Highlights From The Literature
Physiology, October 1, 2007; 22(5): 299 - 302.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.